杭州皓阳生物技术有限公司

Chinese contract development and manufacturing company founded in November 2015 in Hangzhou, Zhejiang, providing technical services for antibody and recombinant protein drug development. Runs close to 7,500 square metres of research and office space across its Hangzhou headquarters and Shanghai branch together with three production bases in Shanghai and Hangzhou totalling more than fifty thousand square metres, and operates technology platforms for antibody druggability assessment, stable cell line development, cell culture process development, purification process development and pilot scale manufacture. Has been recognised as a Hangzhou eaglet enterprise, a municipal enterprise research centre and a national high-tech enterprise, and raised more than eighty million yuan in a Series A round led jointly by Yipu Capital and Haibang Investment.